Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Next-Generation Sequencing Fuels Bioinformatics Upswing

By LabMedica International staff writers
Posted on 25 Nov 2013
The falling cost of genome sequencing is driving momentum to the global next-generation sequencing (NGS) bioinformatics market. More...
As cost-effective technology fuels adoption of genome sequencing in multiple end-user segments, a huge output of NGS data to store and analyze is an overwhelming result. Where primary and secondary data analysis tools are geared to become more valuable as pipelines standardize, the high-value tertiary data analysis segment used for biologic interpretation and clinical reporting will drive revenue growth, according to recent market research.

New analysis from Frost & Sullivan’s (Mountain View, CA, USA), an international growth consultancy firm, revealed that the market earned revenue of USD 170 million in 2012 and estimates this to reach USD 580 million in 2018 at a striking compound annual growth rate (CAGR) of 22.7%.

“With sequencing data production forecast to grow at a CAGR of more than 75% between 2012 and 2018, researchers will need efficient NGS informatics solutions to manage, analyze, and interpret this escalating amount of data,” said Frost & Sullivan life sciences senior industry analyst Christi Bird. “As the number of applications for NGS continues to grow, the implementation of NGS informatics will go up.”

However, customers employ NGS for a broad range of applications, and there is no perfect product for NGS informatics. Therefore, customers may have difficulty in identifying the appropriate tools for their needs. The wide variety of free public domain and commercial applications provided by more than 100 competitors in this field has also led to low barriers to entry, rising competition, and commoditization in specific product fields.

Furthermore, NGS users are frequently tentative in making further investments in commercial informatics tools, because of the range of public and open-source software available along with readily accessible internal bioinformatics resources. Therefore, in addition to the hurdles of commoditization and standardization, suppliers must persuade NGS users their commercial tools are better than free ones.

“As the market matures and informatics prices fall, competitors will rely not just on the expanding volume of users and NGS data developed but also on the high-value interpretation sector of the market to sustain profits globally,” remarked Ms. Bird. “Suppliers that can develop high-value, simple, and streamlined turnkey solutions will find success.”

Related Links:

Frost & Sullivan



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.